🇺🇸 FDA
Pipeline program

A Phase 1, Randomized, Double-Blind, Two-Arm, Two-Way Crossover Study of Pharmacokinetics and Pharmacodynamics of QL0911

QL0911-102

Phase 1 other active

Quick answer

A Phase 1, Randomized, Double-Blind, Two-Arm, Two-Way Crossover Study of Pharmacokinetics and Pharmacodynamics of QL0911 for Immune Thrombocytopenia, Hematopoietic Syndrome of Acute Radiation Syndrome is a Phase 1 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Immune Thrombocytopenia, Hematopoietic Syndrome of Acute Radiation Syndrome
Phase
Phase 1
Modality
other
Status
active

Clinical trials